Laurent Audoly

Company: Prive Bio

Job title: Chief Executive Officer

Bio:

Laurent Audoly, PhD is the cofounder and CEO of PriveBio, a precision medicine company, and a professor and strategic advisor at the Institute for Experiential AI at Northeastern University. He has previously founded and scaled several biotechs across multiple therapeutic areas and serves as a board member of several companies. Dr. Audoly was the founding president and CEO and Kymera Therapeutics (NASDAQ: KYMR) and an advisor at Atlas Venture. Dr. Audoly previously held leadership positions in R&D at Pfizer, Merck and Pierre Fabre Group, where he was the global head of Research & Development and played a pivotal role in eight drug approvals. He holds a PhD in Pharmacology from the Vanderbilt University School of Medicine and completed his post-doctoral fellowship at UNC-Chapel Hill and Duke University.

Seminars:

Building Precision Medicine-Based Approaches to Address End Organ Fibroinflammation in Metabolically Challenged Individuals 9:30 am

Building precision medicine approaches to address end-organ damage in metabolically challenged patients provides the advantage of targeting the root cause of the disease, which leads to personalized, more effective therapies Focusing on fibroinflammation offers the advantage of addressing the specific pathological process driving organ failure, which results in improved clinical outcomes and better long-term quality…Read more

day: Day Two

Panel Discussion: Synthesizing Breakthrough Discoveries to Chart Future Directions for Accelerating Therapeutic Innovation for Broader Patient Impact 2:30 pm

Integrating cross-disciplinary insights for comprehensive understanding to identify synergistic opportunities for more effective drug development strategies Forecasting emerging trends and technologies for proactive research planning to anticipate future challenges for sustainable therapeutic pipelines Fostering global collaborations and partnerships for shared knowledge and resources to expedite clinical translation for faster patient access to novel treatmentsRead more

day: Day Two